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[57] ABSTRACT
Compounds containing two aromatic systems covalently
linked through a linker containing one or more atoms, or
“linker” defined as including a covalent bond perse so as to
space the aromatic systems at a distance 1.5-15 A, are
effective in treating conditions associated with bonedeficits.
The compounds can be administered to vertebrate subjects
alone or in combination with additional agents that promote
bone growth or that inhibit bone resorption. They can be
screened for activity prior to administration by assessing
their ability to effect the transcription of a reporter gene
coupled to a promoter associated with a bone morphogenetic
protein and/or their ability to stimulate calvarial growth in
model animal systems.
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METHODS FOR TREATING BONE DEFICIT
CONDITIONS WITH BENZOTHIAZOLE
This is a continuation of U.S. application Ser. No.
08/735,881 filed Oct. 23, 1986, now abandoned.
TECHNICAL FIELD
The invention relates to compositions and methodsfor use
in limiting undesired boneloss in a vertebrate at risk of such
bone loss, in treating conditions that are characterized by
undesired bone loss or by the need for bone growth, in
treating fractures, and in treating cartilage disorders. More
specifically, the invention concerns the use of specific
classes of compoundsidentified or characterized by a high
throughput screening assay.
BACKGROUND ART
Bone is not a static tissue. It is subject to constant
breakdown and resynthesis in a complex process mediated
by osteoblasts, which produce new bone, and osteoclasts,
which destroy bone. The activities of these cells are regu-
lated by a large number of cytokines and growth factors,
manyof which have now beenidentified and cloned. Mundy
has described the current knowledge related to these factors
(Mundy, G. R. Clin Orthop 324:24—28, 1996; Mundy, G. R.
J Bone Miner Res 8:S505-10, 1993).
Althoughthere is a great deal of information available on
the factors which influence the breakdown and resorption of
bone, information on growth factors which stimulate the
formation of new bone is more limited. Investigators have
searched for sources of such activities, and have found that
bonetissue itself is a storehouse for factors which have the
capacity for stimulating bone cells. Thus, extracts of bovine
bonetissue obtained from slaughterhouses contain not only
structural proteins which are responsible for maintaining the
structural integrity of bone, but also biologically active bone
growth factors which can stimulate bonecells to proliferate.
Amongtheselatter factors are transforming growth factor 6,
the heparin-binding growth factors (acidic and basic fibro-
blast growth factor), the insulin-like growth factors (insulin-
like growth factor I and insulin-like growth factor ID), and a
recently described family of proteins called bone morpho-
genetic proteins (BMPs). All of these growth factors have
effects on other types of cells, as well as on bonecells.
The BMPsare novelfactors in the extended transforming
growth factor 6B superfamily. They were first identified by
Wozney J. et al. Science (1988) 242:1528-34, using gene
cloning techniques, following earlier descriptions character-
izing the biological activity in extracts of demineralized
bone (Urist M. Science (1965) 150:893-99). Recombinant
BMP2 and BMP4 can induce new bone formation when they
are injected locally into the subcutaneous tissues of rats
(Wozney J. Molec Reprod Dev (1992) 32:160-67). These
factors are expressed by normal osteoblasts as they
differentiate, and have been shownto stimulate osteoblast
differentiation and bone nodule formation in vitro as well as
bone formation in vivo (Harris S. et al. J. Bone Miner Res
(1994) 9:855-63). This latter property suggests potential
usefulness as therapeutic agents in diseases which result in
boneloss.
The cells which are responsible for forming bone are
osteoblasts. As osteoblasts differentiate from precursors to
mature bone-formingcells, they express and secrete a num-
ber of enzymes and structural proteins of the bone matrix,
including Type-I collagen, osteocalcin, osteopontin and
alkaline phosphatase (Stein G. et al. Curr Opin Cell Biol
10
15
25
30
35
40
45
50
55
60
65
2
(1990) 2:1018-27; Harris S. et al. (1994), supra). They also
synthesize a number of growth regulatory peptides which
are stored in the bone matrix, and are presumably respon-
sible for normal bone formation. These growth regulatory
peptides include the BMPs (HarrisS.et al. (1994), supra). In
studies of primary cultures of fetal rat calvarial osteoblasts,
BMPs1,2, 3, 4, and 6 are expressed by cultured cells prior
to the formation of mineralized bone nodules (HarrisS. etal.
(1994), supra). Like alkaline phosphatase, osteocalcin and
osteopontin, the BMPsare expressed by cultured osteoblasts
as they proliferate and differentiate.
Although the BMPs are potent stimulators of bone for-
mation in vitro and in vivo, there are disadvantages to their
use as therapeutic agents to enhance bone healing. Receptors
for the bone morphogenetic proteins have been identified in
many tissues, and the BMPs themselves are expressed in a
large variety of tissues in specific temporal and spatial
patterns. This suggests that BMPs may haveeffects on many
tissues other than bone,potentially limiting their usefulness
as therapeutic agents when administered systemically.
Moreover, since they are peptides, they would have to be
administered by injection. These disadvantages impose
severe limitations to the development of BMPsas therapeu-
tic agents.
There is a plethora of conditions which are characterized
by the need to enhance bone formation. Perhaps the most
obvious is the case of bone fractures, where it would be
desirable to stimulate bone growth and to hasten and com-
plete bone repair. Agents that enhance bone formation would
also be useful in facial reconstruction procedures. Other
bone deficit conditions include bone segmental defects,
periodontal disease, metastatic bone disease, osteolytic bone
disease and conditions where connective tissue repair would
be beneficial, such as healing or regeneration of cartilage
defects or injury. Also of great significance is the chronic
condition of osteoporosis, including age-related osteoporo-
sis and osteoporosis associated with post-menopausal hor-
monestatus. Other conditions characterized by the need for
bone growth include primary and secondary
hyperparathyroidism, disuse osteoporosis, diabetes-related
osteoporosis, and glucocorticoid-related osteoporosis. In
addition, or alternatively, the compounds of the present
invention may modulate metabolism, proliferation and/or
differentiation of normal or aberrant cells or tissues.
There are currently no satisfactory pharmaceutical
approaches to managing any of these conditions. Bone
fractures are still treated exclusively using casts, braces,
anchoring devices and other strictly mechanical means.
Further bone deterioration associated with post-menopausal
osteoporosis has been decreased or prevented with estrogens
or bisphosphonates.
U.S. Pat. No. 5,280,040 discloses a class of compounds
which are 3,4-diaryl chromans. These compounds can be
considered derivatives of 2,3,4 triphenyl butanol, where the
hydroxy at the 1-position forms an ether with the ortho
position of the phenyl group substituted at the 4-position of
the butanol. The parent 3,4-diaryl chromans do not contain
nitrogen atoms in the aromatic moieties or their linkers. A
preferred compound, centchroman, contains a nitrogen sub-
stituent only in one of the substituents on a phenyl moiety.
These compoundsare disclosed in the ’040 patent as useful
in the treatment of osteoporosis.
The present invention discloses compounds useful for
limiting or treating bone deficit conditions, and for other
uses that should be apparent to those skilled in the art from
the teachings herein.
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DISCLOSURE OF THE INVENTION
The invention provides compounds that can be adminis-
tered as ordinary pharmaceuticals and have the metabolic
effect of enhancing bone growth. The compounds of the
invention can be identified using an assay for their ability to
activate control elements associated with these factors.
Thus, the invention is directed to methods and compositions
for stimulating the growth of skeletal (bone) tissue, which
methods and compositions use, as active ingredients, com-
pounds wherein two aromatic systems are coupled so as to
be spaced apart from each other by about 1.5 to about 15
Angstroms. The thus-linked systems (including the linker
coupling them) generally include at least one nitrogen atom.
Therefore, the compounds useful in the invention can be
described as having the formula Ar’-linker-Ar?, wherein
each of Ar’ and Ar’ is independently an aromatic system and
the linker portion of the formula spaces Ar’ and Ar? apart by
a distance of approximately 1.5-15 Angstroms. Ar’, Ar? and
the linker may optionally be substituted with non interfering
substituents. In the useful compounds, there is generally at
least one nitrogen atom in either Ar’, Ar* and/orthe linker,
independent of any substituents thereon. Preferably, the
compounds of the invention contain at least one additional
heteroatom selected from the group consisting of N, S and
O, independent of any substituent.
Thus, in one aspect, the invention is directed to a method
to treat a condition in a vertebrate animal characterized by
a deficiency in, or need for, bone growth replacement and/or
an undesirable level of bone resorption, which method
comprises administering to a vertebrate subject in need of
such treatment an effective amount of a compoundof the
formula:
NRtn S L
N
@
Ar! Ar?
wherein
each R* and R? is independently a non-interfering sub-
stituent;
m is an integer of 0-4;
the dotted line represents an optional m bond; and
Lis a flexible non-conjugating linker.
In other aspects, the invention relates to pharmaceutical
compositions for use in the method.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG.1 gives a schematic representation of the compounds
used as active ingredients in the methods of the invention.
FIG. 2 shows the dose response curve for a positive
control compound, designated 59-0008.
FIGS.3 and 4 show illustrative compoundsof the inven-
tion and the results obtained with them in an in vitro test.
MODES OF CARRYING OUT THE INVENTION
Arapid throughput screening test for compounds capable
of stimulating expression of a reporter gene linked to a BMP
promoter (a surrogate for the production of bone morpho-
genetic factors that are endogenously produced) is described
in U.S. application Ser. No. 08/458,434,filed Jun. 2, 1995,
the contents of which are incorporated herein by reference.
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This assay is also described as a portion of a study of
immortalized murine osteoblasts (derived from a mouse
expressing a transgene composed of a BMP2 promoter
driving expression of T-antigen) in Ghosh-Choudhery,N.et
al. Endocrinology (1996) 137:331-39. In this study, the
immortalized cells were stably transfected with a plasmid
containing a luciferase reporter gene driven by a mouse
BMP2promoter (-2736/114 bp), and responded in a dose-
dependent manner to recombinant human BMP2.
Briefly, the assay utilizes cells transformed permanently
or transiently with constructs in which the promoter of a
bone morphogenetic protein, specifically BMP2 or BMP4,is
coupled to a reporter gene, typically luciferase. These trans-
formed cells are then evaluated for the production of the
reporter gene product; compounds that activate the BMP
promoter will drive production of the reporter protein, which
can be readily assayed. Over 40,000 compoundshave been
subjected to this rapid screening technique, and only a very
small percentage are able to elicit a level of production of
luciferase 5-fold greater than that produced by vehicle.
Compounds that activate the BMP promoter share certain
structural characteristics not present in inactive compounds.
The active compounds (“BMPpromoter-active compounds”
or “active compounds”) are useful in promoting bone or
cartilage growth, and thus in the treatment of vertebrates in
need of boneor cartilage growth.
BMPpromoter-active compounds can be examined in a
variety of other assays that test specificity and toxicity. For
instance, non-BMP promoters or response elements can be
linked to a reporter gene and inserted into an appropriate
host cell. Cytotoxicity can be determined by visual or
microscopic examination of BMP promoter- and/or non-
BMPpromoter-reporter gene-containing cells, for instance.
Alternatively, nucleic acid and/or protein synthesis by the
cells can be monitored. For in vivo assays, tissues may be
removed and examined visually or microscopically, and
optionally examined in conjunction with dyes orstains that
facilitate histologic examination. In assessing in vivo assay
results, it may also be useful to examine biodistribution of
the test compound, using conventional medicinal chemistry/
animal model techniques.
As used herein, “limit” or “limiting” and “treat” or
“treatment” are interchangeable terms. The terms include a
postponement of development of bone deficit symptoms
and/or a reduction in the severity of such symptomsthat will
or are expected to develop. The terms further include
ameliorating existing bone or cartilage deficit symptoms,
preventing additional symptoms, ameliorating or preventing
the underlying metabolic causes of symptoms, preventing or
reversing bone resorption and/or encouraging bone growth.
Thus, the terms denote that a beneficial result has been
conferred on a vertebrate subject with a cartilage, bone or
skeletal deficit, or with the potential to develop such deficit.
By “bone deficit” is meant an imbalance in the ratio of
bone formation to bone resorption, such that, if unmodified,
the subject will exhibit less bone than desirable, or the
subject’s bones will be less intact and coherent than desired.
Bone deficit may also result from fracture, from surgical
intervention or from dental or periodontal disease. By “car-
tilage defect” is meant damagedcartilage, less cartilage than
desired, or cartilage that is less intact and coherent than
desired.
Representative uses of the compounds of the present
invention include: repair of bone defects and deficiencies,
such as those occuring in closed, open and non-union
fractures; prophylactic use in closed and open fracture
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reduction; promotion of bone healing in plastic surgery;
stimulation of bone ingrowth into non-cemented prosthetic
joints and dental implants; elevation of peak bone mass in
pre-menopausal women; treatment of growth deficiencies;
treatment of peridontal disease and defects, and other tooth
repair processes; increase in bone formation during distrac-
tion osteogenesis; and treatment of other skeletal disorders,
such as age-related osteoporosis, post-menopausal
osteoporosis, glucocorticoid-induced osteoporosis or disuse
osteoporosis and arthritis. The compounds of the present
invention can also be useful in repair of congenital, trauma-
induced or surgical resection of bone (for instance, for
cancer treatment), and in cosmetic surgery. Further, the
compoundsof the present invention can be used for limiting
or treating cartilage defects or disorders, and may be useful
in wound healing or tissue repair.
Bone or cartilage deficit or defect can be treated in
vertebrate subjects by administering compounds of the
invention which have been identified through suitable
screening assays and which exhibit certain structural char-
acteristics. The compositions of the invention may be
administered systemically or locally. For systemic use, the
compounds herein are formulated for parenteral (e.g.,
intravenous, subcutaneous, intramuscular, intraperitoneal,
intranasal or transdermal) or enteral (e.g., oral or rectal)
delivery according to conventional methods. Intravenous
administration will be by a series of injections or by con-
tinuous infusion over an extended period. Administration by
injection or other routes of discretely spaced administration
will generally be performed at intervals ranging from
weekly to once to three times daily. Alternatively, the
compounds disclosed herein may be administered in a
cyclical manner (administration of disclosed compound;
followed by no administration; followed by administration
of disclosed compound, and the like). Treatment will con-
tinue until the desired outcome is achieved. In general,
pharmaceutical formulations will include a compoundofthe
present invention in combination with a pharmaceutically
acceptable vehicle, such as saline, buffered saline, 5%
dextrose in water, borate-buffered saline containing trace
metals or the like. Formulations may further include one or
more excipients, preservatives, solubilizers, buffering
agents, albumin to prevent protein loss on vial surfaces,
lubricants, fillers, stabilizers, etc. Methods of formulation
are well knownin the art and are disclosed, for example, in
Remington’s Pharmaceutical Sciences, Gennaro, ed., Mack
Publishing Co., Easton Pa., 1990, which is incorporated
herein by reference. Pharmaceutical compositions for use
within the present invention can be in the form ofsterile,
non-pyrogenic liquid solutions or suspensions, coated
capsules, suppositories, lyophilized powders, transdermal
patches or other forms known in the art. Local administra-
tion may be byinjection at the site of injury or defect, or by
insertion or attachment of a solid carrier at the site, or by
direct, topical application of a viscous liquid. For local
administration, the delivery vehicle preferably provides a
matrix for the growing boneor cartilage, and more prefer-
ably is a vehicle that can be absorbed by the subject without
adverse effects.
Delivery of compounds herein to wound sites may be
enhanced by the use of controlled-release compositions,
such as those described in pending U.S. patent application
Ser. No. 07/871,246 (corresponding to WIPO publication
WO 93/20859, which is incorporated herein by reference in
its entirety). Films of this type are particularly useful as
coatings for prosthetic devices and surgical implants. The
films may, for example, be wrapped around the outer sur-
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faces of surgical screws, rods, pins, plates and the like.
Implantable devices of this type are routinely used in
orthopedic surgery. The films can also be used to coat bone
filling materials, such as hydroxyapatite blocks, demineral-
ized bone matrix plugs, collagen matrices and the like. In
general, a film or device as described herein is applied to the
boneat the fracture site. Application is generally by implan-
tation into the bone or attachment to the surface using
standard surgical procedures.
In addition to the copolymers and carriers noted above,
the biodegradable films and matrices may include other
active or inert components. Of particular interest are those
agents that promote tissue growth or infiltration, such as
growth factors. Exemplary growth factors for this purpose
include epidermal growth factor (EGF), fibroblast growth
factor (FGF), platelet-derived growth factor (PDGF), trans-
forming growth factors (TGFs), parathyroid hormone
(PTH), leukemia inhibitory factor (LIF), and insulin-like
growth factors (IGFs). Agents that promote bone growth,
such as bone morphogenetic proteins (U.S. Pat. No. 4,761,
471; PCT Publication WO 90/11366), osteogenin (Sampath
et al. Proc. Natl. Acad. Sci. USA (1987) 84:7109-13) and
NaF (Tencer et al. J. Biomed. Mat. Res. (1989) 23:571-89)
are also preferred. Biodegradable films or matrices include
calcium sulfate, tricalctum phosphate, hydroxyapatite, poly-
lactic acid, polyanhydrides, bone or dermal collagen, pure
proteins, extracellular matrix components and combinations
thereof. Such biodegradable materials may be used in com-
bination with non-biodegradable materials, to provide
desired mechanical, cosmetic or tissue or matrix interface
properties.
Alternative methods for delivery of compounds of the
present invention include use ofALZET osmotic minipumps
(Alza Corp., Palo Alto, Calif.); sustained release matrix
materials such as those disclosed in Wang et al. (PCT
Publication WO 90/11366); electrically charged dextran
beads, as disclosed in Bao et al. (PCT Publication WO
92/03125); collagen-based delivery systems, for example,as
disclosed in Ksander et al. Ann. Surg. (1990) 211(3):288-94;
methylcellulose gel systems, as disclosed in Becket al. J.
Bone Min. Res. (1991) 6(11):1257-65; and alginate-based
systems, as disclosed in Edelman et al. Biomaterials (1991)
12:619-26. Other methods well known in the art for sus-
tained local delivery in bone include porous coated metal
protheses that can be impregnated and solid plastic rods with
therapeutic compositions incorporated within them.
The compoundsofthe present invention may also be used
in conjunction with agents that inhibit bone resorption.
Antiresorptive agents, such as estrogen, bisphosphonates
and calcitonin, are preferred for this purpose. More
specifically, the compounds disclosed herein may be admin-
istered for a period of time (for instance, months to years)
sufficient to obtain correction of a bone deficit condition.
Once the bone deficit condition has been corrected, the
vertebrate can be administered an anti-resorptive compound
to maintain the corrected bone condition. Alternatively, the
compounds disclosed herein may be administered with an
anti-resorptive compound in a cyclical manner
(administration of disclosed compound, followed by anti-
resorptive, followed by disclosed compound,and thelike).
In additional formulations, conventional preparations
such as those described below may be used.
Aqueous suspensions may contain the active ingredient in
admixture with pharmacologically acceptable excipients,
comprising suspending agents, such as methyl cellulose; and
wetting agents, such as lecithin, lysolethicin or long-chain
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fatty alcohols. The said aqueous suspensions may also
contain preservatives, coloring agents, flavoring agents and
sweetening agents in accordance with industry standards.
Preparations for topical and local application comprise
aerosol sprays, lotions, gels and ointments in pharmaceuti-
cally appropriate vehicles which may comprise lowerali-
phatic alcohols, polyglycols such as glycerol, polyethylene
glycol, esters of fatty acids, oils and fats, and silicones. The
preparations may further comprise antioxidants, such as
ascorbic acid or tocopherol, and preservatives, such as
p-hydroxybenzoic acid esters.
Parenteral preparations comprise particularly sterile or
sterilized products. Injectable compositions may be pro-
vided containing the active compound and any of the well
known injectable carriers. These may contain salts for
regulating the osmotic pressure.
If desired, the osteogenic agents can be incorporated into
liposomes by any of the reported methods of preparing
liposomesfor use in treating various pathogenic conditions.
The present compositions may utilize the compounds noted
above incorporated in liposomes in order to direct these
compounds to macrophages, monocytes, other cells and
tissues and organs whichtake up the liposomal composition.
The liposome-incorporated compoundsof the invention can
be utilized by parenteral administration, to allow for the
efficacious use of lower doses of the compounds. Ligands
may also be incorporated to further focus the specificity of
the liposomes.
Suitable conventional methods of liposome preparation
include, but are not limited to, those disclosed by Bangham,
A. D.et al. J Mol Biol (1965) 23:238-252, Olson,F. etal.
Biochim BiophysActa (1979) 557:9-23, Szoka,F. et al. Proc
NatlAcad Sci USA (1978) 75:4194—4198, Mayhew,E.etal.
Biochim Biophys (1984) 775:169175, Kim,S.et al. Biochim
BiophysActa (1983) 728:339:348, and Mayer, et al. Biochim
Biophys Acta (1986) 858:161-168.
The liposomes may be made from the present compounds
in combination with any of the conventional synthetic or
natural phospholipid liposomematerials including phospho-
lipids from natural sources such as egg, plant or animal
sources such as phosphatidylcholine,
phosphatidylethanolamine, phosphatidylglycerol,
sphingomyelin, phosphatidylserine, or phosphatidylinositol.
Synthetic phospholipids that may also be used, include, but
are not limited to: dimyristoylphosphatidylcholine,
dioleoylphosphatidylcholine, dipalmitoylphosphatidylcho-
line and distearoylphosphatidycholine, and the correspond-
ing synthetic phosphatidylethanolamines and phosphati-
dylglycerols. Cholesterol or other sterols, cholesterol
hemisuccinate, glycolipids, cerebrosides, fatty acids,
gangliosides, sphingolipids, 1,2-bis(oleoyloxy)-3-(trimethyl
ammonio) propane (DOTAP), N-[1-(2,3-dioleoyl) propyl-
N,N,N-trimethylammonium chloride (DOTMA), and other
cationic lipids may be incorporated into the liposomes,as is
known to those skilled in the art. The relative amounts of
phospholipid and additives used in the liposomes may be
varied if desired. The preferred ranges are from about 60 to
90 mole percent of the phospholipid; cholesterol, cholesterol
hemisuccinate, fatty acids or cationic lipids may be used in
amounts ranging from 0 to 50 mole percent. The amounts of
the present compounds incorporated into the lipid layer of
liposomes can be varied with the concentration of their
lipids ranging from about 0.01 to about 50 mole percent.
Using conventional methods, approximately 20 to 30% of
the compound present in solution can be entrapped in
liposomes; thus, approximately 70 to 80% of the active
compound is wasted. In contrast, where the compound is
incorporated into liposomes, virtually all of the compound is
incorporated into the liposome, and essentially none of the
active compound is wasted.
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The liposomes with the above formulations may be made
still more specific for their intended targets with the incor-
poration of monoclonal antibodies or other ligands specific
for a target. For example, monoclonal antibodies to the BMP
receptor may be incorporated into the liposome by linkage
to phosphatidylethanolamine (PE) incorporated into the
liposome by the method of Leserman,L.et al. Nature (1980)
288:602-604.
Veterinary uses of the disclosed compounds are also
contemplated. Such uses would include limitation or treat-
ment of bone or cartilage deficits or defects in domestic
animals, livestock and thoroughbred horses. The compounds
described herein can also modify a target tissue or organ
environment, so as to attract bone-forming cells to an
environment in need of such cells.
The compoundsofthe present invention may also be used
to stimulate growth of bone-forming cells or their
precursors, or to induce differentiation of bone-forming cell
precursors, either in vitro or ex vivo. As used herein, the
term “precursor cell” refers to a cell that is committed to a
differentiation pathway, but that generally does not express
markers or function as a mature, fully differentiated cell. As
used herein, the term “mesenchymal cells” or “mesenchy-
mal stem cells” refers to pluripotent progenitor cells that are
capable of dividing many times, and whose progeny will
give rise to skeletal tissues, including cartilage, bone,
tendon,ligament, marrow stroma and connective tissue (see
A. Caplan J. Orthop. Res. (1991) 9:641-50).As used herein,
the term “osteogenic cells” includes osteoblasts and osteo-
blast precursor cells. More particularly, the disclosed com-
pounds are useful for stimulating a cell population contain-
ing marrow mesenchymal cells, thereby increasing the
number of osteogenic cells in that cell population. In a
preferred method, hematopoietic cells are removed from the
cell population, either before or after stimulation with the
disclosed compounds. Through practice of such methods,
osteogenic cells may be expanded. The expanded osteogenic
cells can be infused (or reinfused) into a vertebrate subject
in need thereof. For instance, a subject’s own mesenchymal
stem cells can be exposed to compounds of the present
invention ex vivo, and the resultant osteogenic cells could be
infused or directed to a desired site within the subject, where
further proliferation and/or differentiation of the osteogenic
cells can occur without immunorejection. Alternatively, the
cell population exposed to the disclosed compounds may be
immortalized humanfetal osteoblastic or osteogeniccells. If
such cells are infused or implanted in a vertebrate subject,it
may be advantageous to “immunoprotect” these non-self
cells, or to immunosuppress (preferably locally) the recipi-
ent to enhance transplantation and boneorcartilage repair.
Within the present invention, an “effective amount” of a
composition is that amount which produces astatistically
significant effect. For example, an “effective amount” for
therapeutic uses is the amount of the composition compris-
ing an active compound herein required to provide a clini-
cally significant increase in healing rates in fracture repair;
reversal of bone loss in osteoporosis; reversal of cartilage
defects or disorders; prevention or delay of onset of
osteoporosis; stimulation and/or augmentation of bone for-
mation in fracture non-unionsand distraction osteogenesis;
increase and/or acceleration of bone growth into prosthetic
devices; and repair of dental defects. Such effective amounts
will be determined using routine optimization techniques
and are dependent on the particular condition to be treated,
the condition of the patient, the route of administration, the
formulation, and the judgmentof the practitioner and other
factors evident to those skilled in the art. The dosage
required for the compoundsofthe invention (for example, in
osteoporosis where an increase in bone formationis desired)
is manifested as statistically significant difference in bone
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mass between treatment and control groups. This difference
in bone mass maybeseen, for example, as a 5—20% or more
increase in bone massin the treatment group. Other mea-
surements of clinically significant increases in healing may
include, for example, tests for breaking strength and tension,
breaking strength and torsion, 4-point bending, increased
connectivity in bone biopsies and other biomechanicaltests
well knownto those skilled in the art. General guidance for
treatment regimensis obtained from experiments carried out
in animal models of the disease of interest.
The dosage of the compoundsof the invention will vary
according to the extent and severity of the need for
treatment, the activity of the administered compound, the
general health of the subject, and other considerations well
knownto the skilled artisan. Generally, they can be admin-
istered to a typical human on a daily basis on an oral dose
of about 0.1 mg/kg—1000 mg/kg, and morepreferably from
about 1 mg/kg to about 200 mg/kg. The parenteral dose will
appropriately be 20-100% of the oral dose.
Screening Assays
The osteogenic activity of the compounds used in the
methods of the invention can be verified using in vitro
screening techniques, such as the assessmentof transcription
of a reporter gene coupled to a bone morphogenetic protein-
associated promoter, as described above, or in alternative
assays such as the following:
Technique for Neonatal Mouse Calvaria Assay (In vitro)
This assay is similar to that described by Gowen M. &
Mundy G. J Immunol (1986) 136:2478-82. Briefly, four
days after birth, the front and parietal bones of ICR Swiss
white mouse pups are removed by microdissection and split
along the sagittal suture. The bones are incubated in BGJb
medium (Irvine Scientific, Santa Ana, Calif.) plus 0.02% (or
lower concentration) B-methylcyclodextrin, wherein the
medium also contains test or control substances, at 37° C. in
a humidified atmosphere of 5% CO, and 95% air for 96
hours.
Following this, the bones are removed from the incuba-
tion media and fixed in 10% buffered formalin for 24-48
hours, decalcified in 14% EDTA for 1 week, processed
through graded alcohols; and embedded in paraffin wax.
Three wm sections of the calvaria are prepared. Represen-
tative sections are selected for histomorphometric assess-
ment of bone formation and bone resorption. Bone changes
are measured on sections cut 200 sam apart. Osteoblasts and
osteoclasts are identified by their distinctive morphology.
Other auxiliary assays can be used as controls to deter-
mine non-BMP promoter-mediated effects of test com-
pounds. For example, mitogenic activity can be measured
using screening assays featuring a serum-response element
(SRE) as a promoter and a luciferase reporter gene. More
specifically, these screening assays can detect signalling
through SRE-mediated pathways, such as the protein kinase
C pathway. For instance, an osteoblast activator SRE-
luciferase screen and an insulin mimetic SRE-luciferase
screen are useful for this purpose. Similarly, test compound
stimulation of cAMP response element (CRE)-mediated
pathwayscan also be assayed.For instance,cells transfected
with receptors for PTH and calcitonin (two bone-active
agents) can be used in CRE-luciferase screens to detect
elevated cAMPlevels. Thus, the BMP promoterspecificity
of a test compound can be examined through use of these
types of auxiliary assays.
In Vivo Assay of Effects of Compounds on Murine Calvarial
Bone Growth
Male ICR Swiss white mice, aged 4-6 weeks and weigh-
ing 13—26 gm, are employed, using 4-5 mice per group. The
calvarial bone growth assay is performed as described in
PCTapplication WO 95/24211. Briefly, the test compound
or appropriate control vehicle is injected into the subcuta-
neous tissue over the right calvaria of normal mice.
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Typically, the control vehicle is the vehicle in which the
compound was solubilized, and is PBS containing 5%
DMSO or is PBS containing Tween (2 wl/10 ml). The
animals are sacrificed on day 14 and bone growth measured
by histomorphometry. Bone samples for quantitation are
cleaned from adjacent tissues and fixed in 10% buffered
formalin for 24—48 hours, decalcified in 14% EDTA for 1-3
weeks, processed through graded alcohols; and embeddedin
paraffin wax. Three to five um sections of the calvaria are
prepared, and representative sections are selected for histo-
morphometric assessment of the effects on bone formation
and bone resorption. Sections are measured by using a
camera lucida attachmentto trace directly the microscopic
imageonto a digitizing plate. Bone changes are measured on
sections cut 200 um apart, over 4 adjacent 1x1 mmfields on
both the injected and noninjected sides of the calvaria. New
boneis identified by its characteristic woven structure, and
osteoclasts and osteoblasts are identified by their distinctive
morphology. Histomorphometry software (OsteoMeasure,
Osteometrix, Inc., Atlanta) is used to process digitizer input
to determine cell counts and measure areas or perimeters.
Additional In Vivo Assays
Lead compounds can be further tested in intact animals
using an in vivo, dosing assay. Prototypical dosing may be
accomplished by subcutaneous, intraperitoneal or oral
administration, and may be performed by injection, sus-
tained release or other delivery techniques. The time period
for administration of test compound mayvary (for instance,
28 days as well as 35 days may be appropriate). An
exemplary, in vivo subcutaneous dosing assay may be
conducted as follows:
In a typical study, 70 three-month-old female Sprague-
Dawley rats are weight-matched and divided into seven
groups, with ten animals in each group. This includes a
baseline control group of animals sacrificed at the initiation
of the study; a control group administered vehicle only; a
PBS-treated control group; and a positive control group
administered a compound (non-protein or protein) known to
promote bone growth. Three dosage levels of the compound
to be tested are administered to the remaining three groups.
Briefly, test compound, positive control compound, PBS,
or vehicle alone is administered subcutaneously once per
day for 35 days. All animals are injected with calcein nine
days and two days before sacrifice (two injections of calcein
administered each designated day). Weekly body weights
are determined. At the end of the 35-day cycle, the animals
are weighed and bled by orbital or cardiac puncture. Serum
calcium, phosphate, osteocalcin, and CBCs are determined.
Both leg bones (femur and tibia) and lumbar vertebrae are
removed, cleaned of adhering soft tissue, and stored in 70%
ethanol for evaluation, as performed by peripheral quanti-
tative computed tomography (pQCT; Ferretti, J. Bone
(1995) 17:353S—64S), dual energy X-ray absorptiometry
(DEXA; Laval-Jeantet A. et al. Calcif Tissue Inil (1995)
56:14-18; J. Casez et al. Bone and Mineral (1994)
26:61-68) and/or histomorphometry. The effect of test com-
pounds on bone remodeling can thus be evaluated.
Lead compounds also be tested in acute ovariectomized
animals (prevention model) using an in vivo dosing assay.
Such assays may also include an estrogen-treated group as
a control. An exemplary subcutaneous dosing assay is per-
formed as follows:
In a typical study, 80 three-month-old female Sprague-
Dawley rats are weight-matched and divided into eight
groups, with ten animals in each group. This includes a
baseline control group of animals sacrificed at the initiation
of the study; three control groups (sham ovariectomized
(sham OVX)+vehicle only; ovariectomized (OVX)+vehicle
only; PBS-treated OVX); and a control OVX group that is
administered a compound known to promote bone growth.
Three dosage levels of the compound to be tested are
administered to the remaining three groups of OVX animals.
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Since ovariectomy (OVX) induces hyperphagia,all OVX
animals are pair-fed with sham OVX animals throughoutthe
35 day study. Briefly, test compound, positive control
compound, PBS, or vehicle alone is administered subcuta-
neously once per day for 35 days. Alternatively, test com-
pound can be formulated in implantable pellets that are
implanted for 35 days, or may be administered orally, such
as by gastric gavage. All animals, including sham OVX/
vehicle and OVX/vehicle groups, are injected intraperito-
neally with calcein nine days and two days before sacrifice
(two injections of calcein administered each designated day,
to ensure proper labeling of newly formed bone). Weekly
body weights are determined. At the end of the 35-day cycle,
the animals’ blood and tissues are processed as described
above.
Lead compounds may also be tested in chromic OVX
animals (treatment model). An exemplary protocol fortreat-
mentof established boneloss in ovariectomized animals that
can be used to assess efficacy of anabolic agents may be
performed as follows. Briefly, 80 to 100 six month old
female, Sprague-Dawley rats are subjected to sham surgery
(sham OVX) or ovariectomy (OVX)at time 0, and 10 rats
are sacrificed to serve as baseline controls. Body weights are
recorded weekly during the experiment. After approximately
6 weeks of bone depletion (42 days), 10 sham OVX and 10
OVX rats are randomly selected for sacrifice as depletion
period controls. Of the remaining animals, 10 sham OVX
and 10 OVX rats are used as placebo-treated controls. The
remaining OVX animals are treated with 3 to 5 dosesoftest
drug for a period of 5 weeks (35 days). As a postitive control,
a group of OVX rats can be treated with an agent such as
PTH, a known anabolic agent in this model (Kimmeletal.
Endocrinology (1993) 132:1577-84). To determine effects
on bone formation, the following procedure can be followed.
The femurs, tibiae and lumbar vertebrae 1 to 4 are excised
and collected. The proximalleft and right tibiae are used for
pOCT measurements, cancellous bone mineral density
(BMD)(gravimetric determination), and histology, while
the midshaft of each tibiae is subjected to cortical BMD or
histology. The femurs are prepared for pQCT scanningofthe
midshaft prior to biomechanical testing. With respect to
lumbarvertebrae (LV), LV2 are processed for BMD (pQCT
mayalso be performed); LV3 are prepared for undecalcified
bone histology; and LV4 are processed for mechanical
testing.
Nature of the Compounds Useful in the Invention
All of the compounds of the invention contain two
aromatic systems, Ar and Ar’, spaced apart by a linkerat a
distance of 1.5-15 A, and all generally contain at least one
nitrogen atom. A summary ofthe structural features of the
compounds included within the invention is shown in FIG.
As shown, Ar’ and Ar* may include various preferred
embodiments. These are selected from the group consisting
of a substituted or unsubstituted aromatic ring system con-
taining a five-membered heterocycle; a substituted or unsub-
stituted aromatic ring system containing a six-membered
heterocycle; a substituted or unsubstituted naphthalene moi-
ety; and a substituted or unsubstituted benzene moiety.
There are 16 possible combinationsof these embodimentsif
Ar’ and Ar’, are considered distinguishable. As will be clear,
however, the designation of one aromatic system as Art and
the other as Ar’ is arbitrary; thus there are only ten possible
combinations. However, for simplicity, Ar’ and Ar* are
designated separately with the realization that the choice is
arbitrarily made. All linkers described herein if not
palindromic, are considered link Ar’ to Ar? or vice-versa
whether or not the complementary orientation is explicitly
shown. Thus, if Ar’ and Ar* are different and a linker is
specified as —CONR,it is understood that also included is
the linker —NRCO—.
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The non-interfering substituents on the aromatic system
represented by Ar‘ and the non-interfering substituents on
the aromatic system represented by Ar? are represented in
the formulae herein by R* and R’,respectively. Generally,
these substituents can be of wide variety. Among substitu-
ents that do not interfere with the beneficial effect of the
compounds of the invention on bonein treated subjects are
included alkyl (1-6C, preferably lower alkyl 1-4C),includ-
ing straight or branched-chain formsthereof, alkenyl (1-6C,
preferably 1-4C), alkynyl (1-6C, preferably 1-4C),all of
which can be straight or branched chains and may contain
further substituents; halogens, including F, Cl, Br and I;
siloxy, OR, SR, NR,, OOCR, COOR, NCOR, NCOOR,andbenzoyl, CF,, —OCF,, SCF, —N(CF;)., CN, SO, SOR
and SO;R wherein R is alkyl (1-6C) or is H. Where R* or
R? substituents are in adjacent positions in the aromatic
system, they may form aring. Further, rings may be included
in substituents which contain sufficient carbon and heteroa-
toms to provide this possibility.
Preferred non-interfering substituents include hydrocar-
byl groups of 1-6C, including saturated and unsaturated,
linear or branched hydrocarbyl as well as hydrocarbyl
groups containing ring systems; halo groups, alkoxy,
hydroxy, amino, monoalkyl- and dialkylamino where the
alkyl groups are 1-6C, CN, CF, and COOR.Although the number of R' and R? maytypically be 0-4
or 0-5 depending on the available positions in the aromatic
system, preferred embodiments include those wherein thenumber of R? is 0, 1 or 2 and of R? is 0, 1 or 2.
The linker group, L, may be a covalent bond or any group
having a valence of at least two and covering a linear
distance of from about 1.5 to about 15 Angstroms,including
those that contain cyclic moieties, that meet this spatial
requirement. Useful linkers are divided, by definition herein,
into three general categories: (1) flexible non-conjugating
linkers, (2) flexible conjugating linkers, and (3) constrained
linkers. The preferred choice of linker will depend on the
choices for Ar’ and Ar’.
As defined herein, flexible non-conjugating linkers are
those that link only one position of Ar’ to one position of
Ar’, and provide only a single covalent bond or a single
chain between Ar’ and Ar’. The chain may contain branches,
but may not contain a-bonds (except in the branches) or
cyclic portions in the chain. The linker atoms in the chain
itself rotate freely around single covalent bonds, and thus the
linker has more than two degrees of freedom. Particularly
useful flexible non-conjugating linkers, besides a covalent
bond,are those of the formulae: —NR—, —CR.,—, —S—,
or —O—, wherein R is H or alkyl (1-6C), more preferably
H or lower alkyl (1-4C) and more preferably H. Also
preferred are those of the formulae: —NRCO—,—CONR—, —CR,S—, —SCR,—, —OCR,—,—CR,0—, —NRNR—, —CR,CR,—, —NRSO,—,—SO,NR—, —CR,CO—, —COCR,—, and —NR—
NR—CO—CR,— and its complement —CR,—CO—
NR—NR-—,,including the isosteres thereof. Also preferred
are those of the formulae: —NR(CR,),NR—, —O(CR,)
20—, and —S(CR,).S—, including the isosteres thereof.
The optimum choice of linker is dependent on the nature of
Ar’ and Ar’.
Flexible conjugating linkers are those that link only one
position ofAr’ to oneposition ofAr’, but incorporate at least
one double or triple bond or one or more cyclic systems and
thus have only two degrees of freedom. A flexible conju-
gating linker may form a completely conjugated a-bond
linking system between Ar’ and Ar’, thus providing for
co-planarity of Art and Ar*. Examples of useful flexible
conjugating linkers include: —RC—CR—; —N=N—;
—C=C—,; —RC=N—; —N=CR—; —NR—N=CR—;
—NR—NR—CO—CR=CR—, and the like, where R is H
or alkyl (1-6C); preferably H or lower alkyl (1-4C); and
more preferably H.
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Constrained linkers are those that have more than onepoint of attachmentto either or both Ar’ and Ar? and, thus,
generally allow for only one degree of freedom. Constrained
linkers most frequently form fused 5- or 6-membered cyclic
moieties with Ar’ and/or Ar? where either Ar’ or Ar* hasat
least one substituent appropriately positioned to form a
second covalent bond with the linker, e.g., where Aris a
phenyl group with a reactive, ortho-positioned substituent,
or is derivatized to the linker directly at the ortho position.
(Although the aromatic moieties should properly be refined
to as phenylene or naphthylene in such cases, generally the
term “phenyl” or “naphthyl” is used herein to include both
monovalent and bivalent formsof these moieties). Examples
of particularly useful constrained linkers include
oO
ompeG.eseeeet
and the like, where X is O, N, S or CR, and Y is CR, or
C=O.
Ar’ is an aromatic system containing a five-membered
heterocycle, of the formula:“QD
wherein the dotted line represents an optional a-bond;
each R’ is independently a non-interfering substituent;
and
m is an integer of 0-4.
The nature of the R* and R?is outlined above. Preferably,
Lis selected from the group consisting of —NRCO— and
—CONR—, wherein R is H or alkyl (1-6C) and R® is
—NR, or —OR where each R is independently H or alkyl
(1-6C). The preferred compoundis selected from the group
consisting of Compound Nos. 59-0102 and 59-0070.
Synthesis of the Compounds Useful in the Invention
Many of the compounds useful in the invention are
commercially available and can be synthesized by art-
known methods. Those compounds useful in the invention
which are new compounds, can similarly be obtained by
methods generally knownin theart.
The following examplesare intendedto illustrate, but not
to limit, the invention.
oO
\
Preparation A
Compound 59-0008 was synthesized according to the
procedure of McDonald, W.S., et al. Chem Comm (1969)
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392-393; Irving, H. N. N. H.et al. Anal Chim Acta (1970)
49:261-266. Briefly, 10.0 g of dithizone was taken up in 100
ml EtOH and 50 ml AcOH and heated at reflux for 18 h.
After cooling, this was diluted first with 100 ml water and
then with 50 ml 1N NaOH.This wasthen further neutralized
by the addition of 6N NaOH to bring the pH to 5.0. This
deep purple mixture was then concentrated on a rotavaporto
remove organics. Once the liquid hadlostall of its purple
color, this was filtered to collect the dark precipitate. Puri-
fication by flash chromatography (4.5x25.7 cm; EtAc/Hep.
(1:4); R,0.22) followed by recrystalization from EtOH gave
2.15 ¢ 05% yield) of dark purple crystals, mp=184—-185° C.
*H NMR (CDCL) 7.90 (d of d, J,=7.7, J,=2.2, 2H), 7.64
(hump, 1H), 7.49 (m, 3H), 7.02 (m, 1H), 6.91 (m, 2H), 6.55
(d, J=8.1, 1H). MS (ED) 254 (47, M+), 105 (26), 77 [100], 51
(27). HRMS(EI, M+) 254.0626 (caled 254.0626182). Anal.
Caled for C,3H,N.S: C, 61.40; H, 3.96; N, 22.03. Found:
C, 61.40; H, 4.20; N, 22.06.
EXAMPLE1
High Throughput Screening
Several thousand compounds were tested in the assay
system set forth in U.S. Ser. No. 08/458,434,filed Jun. 2,
1995, and incorporated herein by reference. The standard
positive control was a compound of the invention, 59-0008
(also denoted “OS8”), which is of the formula:
H
Nw Nol)
"OSg"
In more detail, the 2T3-BMP-2-LUCcells, a stably trans-
formed osteoblast cell line described in Ghosh-Choudhuryet
al. Endocrinology (1996) 137:331-39, referenced above,
was employed. The cells were cultured using a-MEM, 10%
FCS with 1% penicillin/streptomycin and 1% glutamine
(“plating medium”), and were split 1:5 once per week. For
the assay, the cells were resuspended in a plating medium
containing 4% FCS,plated in microtiter plates at a concen-
tration of 5x10° cells (in 50 yl)/well, and incubated for 24
hours at 37° C. in 5% CO,,.Toinitiate the assay, 50 wl of the
test compound or the control in DMSO was added at 2x
concentration to each well, so that the final volume was 100
Hi. The final serum concentration was 2% FCS,andthefinal
DMSOconcentration was 1%. Compound 59-0008 (10 uM)
was used as a positive control.
Thetreated cells were incubated for 24 hours at 37° C. and
5% CO,. The medium was then removed,and the cells were
rinsed three times with PBS. After removal of excess PBS,
25 wl of 1x cell culture lysing reagent (Promega #E153A)
was added to each well and incubated for at least ten
minutes. Optionally, the plates/samples could be frozen at
this point. To each well was added 50 wl of luciferase
substrate (Promega #E152A; 10 ml Promegaluciferase
assay buffer per 7 mg Promegaluciferase assay substrate).
Luminescence was measured on an automated 96-well
luminometer, and was expressed as either picograms of
luciferase activity per well or as picograms of luciferase
activity per microgram of protein.
In this assay, compound 59-0008 (3-phenylazo-1H-4,1,2-
benzothiadiazine) exhibited a pattern of reactivity, as shown
in FIG. 2. The activity for compound 59-0008 was maximal
at a concentration of approximately 3-10 uM and, more
particularly, at about 3 uM,and thus provided a response of
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approximately 175 light emission units. Accordingly, other
tested compounds were evaluated at various concentrations,
and these results were comparedto the results obtained for
59-0008 at 10 uM (which value was normalized to 100). For
instance, any tested compound in FIG. 3 and FIG. 4 that
showed greater activity than 10 uM of 59-0008 would result
in a value over 100.
As shown in FIG. 3 (46 sheets) and FIG. 4 (28 sheets),
several compounds were found to be particularly effective.
EXAMPLE 2
In Vivo Calvarial Bone Growth Data
Compound 59-0008 was assayed in vivo according to the
procedure described previously (see “In vivo Assay of
Effects of Compounds on Murine Calvarial Bone Growth”,
supra). As compared to a vehicle control, compound
59-0008 induced a 4-fold increase in width of new calvarial
bone.
EXAMPLE3
Chondrogenic Activity
Compounds 59-008, 59-0102 and 50-0197 were assayed
for effects on the differentiation of cartilage cells, as com-
pared to the action of recombinant human BMP-2.Briefly,
a mouse clonal chondrogenic cell line, TMC-23, was iso-
lated and cloned from costal cartilage of transgenic mice
containing the BMP-2 gene control region driving SV-40
large T-antigen, generated as described in Ghosh-Choudhury
et al Endocrinology 137:331-39, 1996. These cells were
cultured in DMEM/10% FCS, and were shown to express
T-antigen, and also to produce aggrecan (toluidine blue
staining at pH 1.0) and Type-II collagen (immunostaining)
by 7 days after confluence.
For measurementof alkaline phosphatase (ALP)activity,
the technique of LF Bonewald et al. J Biol Chem (1992)
267:8943-49, was employed. Briefly, TMC-23 cells were
plated in 96 well microtiter plates in DMEM containing 10%
FCS at 4x10° cellsAwell. Two daysafter plating, the cells
were confluent and the medium was replaced with fresh
medium containing 10% FCSanddifferent concentrations of
compounds or recombinant BMP-?2.After an additional 2 or
5 days incubation, the plates were washed twice with PBS,
and then lysing solution (0.05% Triton X-100) was added
(100 yl/well). The cells were lysed by three freeze-thaw
cycles of -70° C. (30 min), followed by 37° C.(30 min with
shaking). Twenty microliters of cell lysates were assayed
with 80 wl of 5 mM p-nitrophenol phosphate in 1.5 M
2-amino-2-methyl-propanol buffer, pH 10.3 (SigmaALP kit,
Sigma Chemical Co., St. Louis, Mo.) for 10 min at 37° C.
The reaction was stopped by the addition of 100 wl of 0.5 M
NaOH.The spectrophotometric absorbance at 405 nm was
compared to that of p-nitrophenol standards to estimate ALP
activity in the samples. The protein contentof the cell lysates
was determined by the Bio-Rad protein assay kit (Bio-Rad,
Hercules, Calif.). Specific activity was calculated using
these two parameters.
At day 2, compounds 59-0008 (10-° M), 59-0102 (10-7
M) and 59-0197 (10°? M) increased ALP levels approxi-
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mately 3-, 2- and 2.5-fold, respectively, as compared to the
vehicle control. Recombinant BMP2 at 100, 50 or 10 ng/ml
induced ALP levels approximately 10-, 4- or 1.5-fold,
respectively, as compared to the vehicle control.
EXAMPLE4
Synthesis of Exemplary Compounds
Compounds of the invention can be synthesized by the
procedures described in Dryanska, V. and Ivanov, K. Syn-
thesis (1976) 1:37-8, using the described embodiment of
Ar’and the appropriate analog of the benzothiazole embod-
ied in Ar’.
Alternates to the olefin linker described can also be
prepared using standard methods.
We claim:
1. A method to treat a condition in a vertebrate animal
characterized by a deficiency in, or need for, bone growth
replacement and/or an undesirable level of bone resorption,
which method comprises administering to a vertebrate sub-
ject in need of such treatment an effective amount of a
compound of the formula:
@)
NOON
wherein
each R* and R? is independently a non-interfering sub-
stituent;
m is an integer of 0-4;
the dotted line represents an optional a bond; and
Lis a flexible non-conjugating linker.
2. The method of claim 1 wherein L is selected from the
group consisting of —NRCO— and —CONR—,wherein R
is H or alkyl (1-6C).
3. The method of claim 1 wherein R* is —NR, or —OR
where each R is independently H or alkyl (1-6C).
4. The method of claim 1 wherein said compound is
selected from the group consisting of Compound Nos.
59-0102 and 59-0070.
5. The method of claim 1 wherein said condition is
osteoporosis, bone fracture or deficiency, primary or sec-
ondary hyperparathyroidism, periodontal disease or defect,
metastatic bone disease, osteolytic bone disease, post-plastic
surgery, post-prosthetic joint surgery, or post-dental implan-
tation.
6. The method of claim 1 which further comprises admin-
istering to said subject one or moreagents that promote bone
growth or that inhibit bone resorption.
7. The method of claim 6 wherein said agents are selected
from the group consisting of bone morphogenetic factors,
anti-resorptive agents, osteogenic factors, cartilage-derived
morphogenic proteins, growth hormones,and differentiating
factors.
